Intravenous ascorbic acid given at pharmacologic doses (typically 10–100+ grams) to reach plasma levels oral vitamin C cannot. Used in longevity and integrative clinics for immune support, recovery, and as an investigational cancer adjunct. Requires G6PD and renal screening; it is not FDA-approved as a cancer treatment, and outcome evidence outside deficiency states is mixed.
High-Dose Vitamin C IV Therapy (also called pharmacologic intravenous ascorbic acid) infuses grams of vitamin C—often 10–25 g in wellness settings and 25–100+ g in investigational oncology protocols—directly into a vein. Oral vitamin C saturates intestinal transporters at a few hundred milligrams a day. NIH pharmacokinetic work showed that only the IV route produces plasma concentrations in the millimolar range, roughly 30- to 70-fold higher than the oral ceiling.
How It’s Used
A typical longevity-clinic visit dilutes sodium ascorbate or ascorbic acid in sterile water or a compatible fluid and infuses it over 30–120+ minutes, rate-limited by vein comfort and osmolarity. Lower “immune” bags (5–15 g) overlap with Myers-type drips. Higher doses are a different intervention: they generate hydrogen peroxide in the extracellular space in vitro and have been studied as an adjunct around chemotherapy or radiation—not as a stand-alone cancer cure. Glutathione, if given, is sequenced after vitamin C in a separate syringe; mixing them in one bag can oxidize GSH.
Evidence Positioning
The biochemistry is solid; the clinical outcomes are not. Padayatty and colleagues mapped IV-versus-oral pharmacokinetics. Laboratory and early translational papers (including Chen et al. and a 2014 ovarian-cancer study) support a pro-oxidant, peroxide-mediated effect on some tumor cells at pharmacologic concentrations. Systematic reviews of IV vitamin C in cancer find signals for quality-of-life and toxicity mitigation in selected cohorts, but randomized survival benefit remains unproven. For colds, energy, and “immune boosting” in replete adults, high-dose IV C is elective and under-studied relative to its marketing. Position it as a screened, dose-defined adjunct—not as FDA-approved oncology or a substitute for vaccines, antivirals, or standard cancer care.
Safety
Two non-negotiable screens: G6PD (high-dose ascorbate can trigger hemolysis in deficiency) and kidney function (oxalate generation and rare oxalate nephropathy, especially with dehydration or prior stones). Other cautions include hemochromatosis/iron overload, significant heart failure if large fluid volumes are used, and vein irritation from hypertonic solutions. Use USP <797> compounding, labeled milligram doses, and a slow-down protocol for flushing or burning.
Summary
High-dose vitamin C IV is pharmacologic ascorbate—a different drug exposure than oral supplements. It is biologically interesting, screening-intensive, and easy to oversell. Ask for the gram dose, G6PD and creatinine results, and a written plan before you sit down for the drip.
Complete G6PD testing before the first high-gram session (and after any result the clinic has not seen). Eat a light meal and hydrate well. Bring a medication list and disclose kidney stones, iron overload, G6PD deficiency, pregnancy, and current cancer treatment. Wear a sleeve that rolls above the elbow. Expect glutathione, if used, to be given last in a separate syringe.
Most people resume normal activity the same day. Increased urination, thirst, a cool or burning sensation along the vein, and transient fatigue or lightheadedness can occur. Keep drinking water unless restricted. Dark urine, severe back pain, shortness of breath, or jaundice after a high-dose session needs prompt medical care.
Hemolysis in G6PD deficiency; oxalate kidney injury or stones, especially if dehydrated or renally impaired; vein irritation/phlebitis from hypertonic solutions; fluid overload if a large bag is used in heart failure; dizziness or hypoglycemia-like symptoms during rapid infusion; rare hypersensitivity. High-dose IV vitamin C is not FDA-approved to treat or cure cancer and should not delay standard oncology care.
Padayatty S.J. et al. Vitamin C Pharmacokinetics: Implications for Oral and Intravenous Use (Ann Intern Med, 2004).
https://doi.org/10.7326/0003-4819-140-7-200404060-00010Padayatty S.J. et al. Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects (PLoS One, 2010).
https://doi.org/10.1371/journal.pone.0011414Chen Q. et al. Pharmacologic Ascorbic Acid Concentrations Selectively Kill Cancer Cells: Action as a Pro-Drug to Deliver Hydrogen Peroxide to Tissues (Proc Natl Acad Sci USA, 2005).
https://doi.org/10.1073/pnas.0506390102Ma Y. et al. High-Dose Parenteral Ascorbate Enhanced Chemosensitivity of Ovarian Cancer and Reduced Toxicity of Chemotherapy (Sci Transl Med, 2014).
https://doi.org/10.1126/scitranslmed.3007154Nauman G. et al. Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials (Antioxidants, 2018).
https://doi.org/10.3390/antiox7070089Levine M., Padayatty S.J., Espey M.G. Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic Discoveries (Adv Nutr, 2011).
© 2026 Longevity Clinic Finder. All rights reserved.
Designed by SMBPulse
CDC. Injection Safety and Safe Practices (One & Only Campaign).
https://www.cdc.gov/injection-safety/USP <797> Sterile Compounding Standards (overview).
https://www.usp.org/compounding/usp-compounding-standardsCost Range
$150–$400 for modest (about 10–25 g) wellness infusions; $300–$800+ for higher-gram investigational protocols (market- and dose-dependent).
Frequency
Wellness clinics may offer weekly or biweekly visits during a defined block, then as needed. Investigational oncology adjunct schedules follow the treating clinician. There is no evidence-based “maintenance” drip for healthy, replete adults.
Adults who have documented G6PD and renal screening, a specific goal (recovery adjunct, clinician-directed protocol), and a clear understanding that cancer and immune-boosting claims outpace randomized evidence. Poor candidates include G6PD deficiency, significant kidney disease or active oxalate stone disease, untreated iron overload, and anyone substituting IVC for indicated medical or oncologic treatment.
Explore nearby clinics, compare profiles, and find providers offering this treatment.
Find Clinics Near You© 2026 Longevity Clinic Finder. All rights reserved.
Designed by SMBPulse
Your Privacy Choices